Arvinas, Inc. (ARVN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Arvinas, Inc. (ARVN) closed at USD 6.82 on 2026-10-14, a change of -28.2 % over the past year, with a market capitalization of USD 468.17M.

Arvinas, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Arvinas, Inc. key figures

Previous close

USD 6.82 (2026-10-14)

1-year change

-28.2 %

Market cap

USD 468.17M

Enterprise value

USD -91.73M

P/E ratio (trailing)

26.52

P/E ratio (forward)

-2.22

EPS (trailing)

0.27

EPS (forward)

-3.23

PEG ratio

n/a

Price to book

0.83

Revenue growth

1,014.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.31

Employees

246

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Arvinas, Inc.

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma G12D protein for the treatment of cancers with the G12D mutation comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), which are investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Arvinas, Inc. and compare it with other stocks.